Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will take part in multiple investor conferences and fireside chats in early March 2026, including TD Cowen (March 3), UBS Biotech Summit (March 9), Leerink (March 10), Jefferies Biotech on the Beach (March 11), and Barclays (March 12).
Live webcasts of each presentation will be available under News and Events in the Investors section of the company website, with replays archived after the events.
Positive
- None.
Negative
- None.
News Market Reaction – KYMR
In the Feb 24 session, KYMR gained 2.92%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings timing update | Neutral | +0.1% | Announced date and webcast details for Q4 and full-year 2025 results. |
| Feb 04 | Investor conferences | Neutral | +0.6% | Participation in February 2026 investor fireside chats and related webcasts. |
| Jan 29 | Clinical trial progress | Positive | +3.9% | First patient dosed in BREADTH Phase 2b asthma trial of KT-621. |
| Jan 13 | Strategy and cash update | Positive | +1.4% | Outlined 2026 objectives and reported an estimated $1.6B cash runway. |
| Jan 06 | Major conference presentation | Neutral | +1.4% | Previewed J.P. Morgan Healthcare Conference presentation and webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent KYMR news, from conferences to clinical progress and strategy updates, has generally been followed by modestly positive price reactions, especially around clinical and cash runway disclosures.
This announcement continues a steady cadence of investor outreach for Kymera Therapeutics. In January–February 2026, the company highlighted upcoming earnings timing, multiple investor conferences, and a key clinical milestone: first patient dosed in the BREADTH Phase 2b asthma trial of KT-621, with data timelines into 2027. A January strategy update paired this pipeline progress with an estimated $1.6 billion cash position supporting plans into 2029, framing the March conferences as part of an ongoing communication program.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
- TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;
- Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; and
- Barclays 28th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET.
In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit on March 9 and March 11, respectively.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
Vice President, Corporate Communications
mhenson@kymeratx.com
857-285-5300
